Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 13, Issue 3, 2011, Pages 251-257

  Bolli, G B ^a   Luzio, S ^b   Marzotti, S ^a   Porcellati, F ^a   Sert Langeron, C ^c   Charbonnel, B ^d   Zair, Y ^d   Owens, D R ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c SANOFI   (France)

^d INSERM   (France)

Author keywords

Insulin analogues; Insulin aspart; Insulin glulisine; Insulin therapy; Obesity; Obesity therapy; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLULISINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BOLUS INJECTION; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DIABETIC PATIENT; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PAIN; INSULIN BLOOD LEVEL; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TEST MEAL;

EID: 78851472325     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01343.x     Document Type: Article

References (23)

1. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
2. Akalin S, Berntorp K, Ceriello A et al. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract 2009; 63: 1421-1425.
3. Albarrak AI, Luzio SD, Chassin LJ, Playle RA, Owens DR, Hovorka R. Associations of glucose control with insulin sensitivity and pancreatic beta-cell responsiveness in newly presenting type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 198-203.
4. Heinemann L, Chantelau EA, Starke AA. Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin. Diabete Metab 1992; 18: 21-24.
5. Becker RH. Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther 2007; 9: 109-121.
6. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47: 7-20.
7. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005; 113: 435-443.
8. Heise T, Nosek L, Spitzer H et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007; 9: 746-753.
9. Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR. A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period. Diabetes Res Clin Pract 2008; 79: 269-275.
10. Becker RH, Frick AD, Burger F, Scholtz H, Potgieter JH. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005; 113: 292-297.
11. Becker RH, Frick AD, Nosek L, Heinemann L, Rave K. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care 2007; 30: 2506-2507.
12. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005; 28: 2100-2105.
13. Arnolds S, Rave K, Hovelmann U, Fischer A, Sert-Langeron C, Heise T. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2010; 118: 662-664.
14. Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007; 30: 2447-2452.
15. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies, 2nd edn. Revised and Expanded. New York: Marcel Dekker, 2000.
16. Sluzky V, Tamada JA, Klibanov AM, Langer R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci U S A 1991; 88: 9377-9381.
17. Bakaysa DL, Radziuk J, Havel HA et al. Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: dissociation of a protein-ligand complex. Protein Sci 1996; 5: 2521-2531.
18. Bhatnagar S, Srivastava D, Jayadev MS, Dubey AK. Molecular variants and derivatives of insulin for improved glycemic control in diabetes. Prog Biophys Mol Biol 2006; 91: 199-228.
19. Vora JP, Burch A, Peters JR, Owens DR. Absorption of radiolabelled soluble insulin in type 1 (insulin-dependent) diabetes: influence of subcutaneous blood flow and anthropometry. Diabet Med 1993; 10: 736-743.
20. Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care 1992; 15: 1484-1493.
21. Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care 1995; 18: 986-991.
22. ter Braak EW, Woodworth JR, Bianchi R et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1437-1440.
23. Bergenstal RM, Johnson M, Powers MA et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008; 31: 1305-1310.